Published - August 8th, 2023 @ 3:35 PM (GMT+2)

Novavax (NASDAQ:NVAX), a prominent biotech company, reported a surprising second-quarter profit on Tuesday, driven by robust revenue from its COVID-19 vaccines. The company's shares jumped as much as 20% in premarket trading, reflecting a significant turnaround from previous doubts about its ability to stay in business.

Q2 Financial Highlights: Strong Revenue & Profit
‍

Novavax posted a net income of $58 million, or $0.58 per share, for the quarter, compared to a net loss of $510 million, or $6.53 a share, a year earlier. The company generated second-quarter sales of $424.4 million, up from $185.9 million from the same period a year ago and well above analysts' estimates of $240 million.

The company also entered into a stock purchase agreement with SK Bioscience Co, under which Novavax will issue 6.5 million shares to the South Korean company at $13 per share. SK Bioscience will also purchase $85 million in Novavax's common stock at $13 per share, reflecting a 59% premium to the past 90-day trading value.
‍

Novavax trimmed its full-year forecast for sales of the COVID-19 vaccine, now expecting between $1.3 billion and $1.5 billion in sales and grants this year, compared to its earlier forecast of $1.4 billion to $1.6 billion. The adjustment reflects part of a cash settlement with the Canadian government and does not include the $100 million in cash Canada paid during the second quarter.

Updated Vaccine & Cost-Cutting Measures:
‍

Novavax is counting on selling an updated version of its shot in the fall season, especially in the United States. The company has developed an updated vaccine candidate targeting the XBB.1.5 coronavirus variant and is manufacturing commercially to meet the U.S. government's timeline for regulatory action in September.

The company is also executing a global cost-cutting plan, slashing 25% of its workforce and consolidating facilities and infrastructure. This plan is expected to reduce 2024 research and development and selling, general, and administrative expenses costs by approximately 40% to 50% compared with 2022.

‍

Challenges & Opportunities Ahead:
‍

Novavax's stock has lost around 95% of its value since last year as the company grappled with weak demand for its COVID-19 vaccines after being a late entrant in a market dominated by Pfizer-BioNTech, Moderna, and AstraZeneca. However, the company's promising vaccine pipeline and strategic agreements, such as the one with SK Bioscience, provide a positive outlook for the future.

‍
‍

Conclusion
With a surprise profit, substantial revenue, and strategic plans for the future, Novavax is on the right track. The company's focus on updated vaccines, cost-cutting measures, and strategic partnerships positions it well for future growth in the competitive vaccine market.

‍

‍
The information on mexem.com is for general informational purposes only. It should not be regarded as investment advice. Investing in stocks involves risk. A stock's past performance is not a reliable indicator of its future performance. Always consult a financial advisor or trusted sources before making any investment decisions

‍
‍